mRNA-based prophylactic vaccinesin collaboration with GSK
Addressing infectious diseases
Multivalent Constructs
Seasonal Influenza vaccine candidates(Modified mRNA)
Partner
FLU SV mRNA
Influenza vaccine candidate(Modified mRNA)
Partner
Avian Influenza (H5N1)
Monovalent Candidate
Partner
CV0601/CV0701
COVID-19
Partner
Other infectious diseases
Partner
RNA-based cancer immunotherapies
CVGBM
Multi-epitope mRNA cancer vaccine candidateSurgically resected glioblastoma
Phase 1 study details
Email address for interested patients: glioblastoma.trial@curevac.com
CVGBM is CureVac’s first investigational cancer vaccine based on its proprietary second-generation mRNA backbone. It encodes a single fusion protein comprising eight epitopes derived from tumor-associated antigens (TAA) with relevance in glioblastoma, including HLA class I epitopes presented on HLA A0201 and class II epitopes. The applied epitopes have been previously shown to induce immune responses in glioblastoma patients when administered as peptide vaccines with adjuvants. CVGBM applies unmodified mRNA and is formulated within lipid nanoparticles (LNPs).
Off-the-Shelf Cancer Vaccines
Undisclosed
Personalized Cancer Vaccines
Undisclosed
Molecular therapies
Cas9 gene-editing
Partner
Gene-editing – Pre-clinical
CureVac is collaborating with CRISPR Therapeutics to develop novel Cas9 mRNA constructs, which have improved properties for gene editing applications, such as increased potency, decreased duration of expression, and reduced potential for immunogenicity.
For more information about our partnership with CRISPR click here.
Ocular diseases
Partner
Therapeutic antibodies
Partner